Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...

GeoVax Labs' Mpox vaccine still has a long way to go before gaining approval or generating any type of revenue. Its treatment is still in pre-clinical development. That phase of development alone ...

Ethical Vaccine Development & Public Confidence – GeoVax embraces open regulatory processes, rigorous safety standards, and public access to data, ensuring confidence in its vaccines. These principles ...

GeoVax senior management will also conduct one-on-one meetings throughout the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax ...

Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum. ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE) - GeoVax Labs, ...

Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...

GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The company’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.66. About GeoVax Labs ...

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness. ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York und ...

Geovax Labs (NASDAQ:GOVX) just reported results for the second quarter of 2024. Geovax Labs reported earnings per share of -$1.99. This was above the analyst estimate for EPS of -$4.43.

ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J.

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...